Results 21 to 30 of about 32,127 (239)

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate

Haematologica, 2014
Clinical significance of the JAK2V617F mutation in patients with a myeloproliferative neoplasm has been the target of intensive research in recent years. However, there is considerably uncertainty about prognosis in JAK2V617F positive individuals without
Camilla Nielsen, Stig E. Bojesen, Børge G. Nordestgaard, Klaus F. Kofoed, Henrik S. Birgens   +4 more
doaj   +1 more source

Extracranial carotid artery aneurysm with myeloproliferative neoplastic cell invasion

Journal of Vascular Surgery Cases and Innovative Techniques, 2020
The major causes of rare extracranial carotid artery aneurysms are arteriosclerosis, trauma, and radiation therapy. Here, we describe a patient with an extracranial carotid artery aneurysm caused by a myeloproliferative neoplasm.
Shotaro Ogawa, MD, Masanori Yoshino, MD, PhD, Takayuki Hara, MD, PhD   +2 more
doaj   +1 more source

IL-4 Serum Level Estimation in Myeloproliferative Neoplasm Patients

مجلة مركز بحوث التقنيات الاحيائية, 2022
Back Ground: Myeloproliferative neoplasm (MPN) is a long-term blood disease that has an excess production of mature hematopoietic pluripotent stem cells in the bone marrow. In the early fifties, W.
Ahmed Rushdi Abdullah
doaj   +1 more source

Myelodysplastic/Myeloproliferative Neoplasms [PDF]

, 2013
AbstractThe myelodysplastic syndrome-myeloproliferative neoplasms (MDS/MPNs) are a heterogeneous group of hematologic malignancies characterized by dysplastic and myeloproliferative clinical, laboratory, and morphological overlapping features, both in marrow and in blood.
Faramarz Naeim, P. Nagesh Rao, Sophie X. Song, Ryan T. Phan   +3 more
openaire   +5 more sources

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients

Haematologica, 2011
Within a cohort of 1,915 consecutive patients with myeloproliferative neoplasm followed for a median time of 5.2 years (range 0–33.3), we investigated the occurrence of lymphoid neoplasm with the aim of defining this risk and to investigate the role of ...
Elisa Rumi, Francesco Passamonti, Chiara Elena, Daniela Pietra, Luca Arcaini, Cesare Astori, Silvia Zibellini, Emanuela Boveri, Cristiana Pascutto, Mario Lazzarino   +9 more
doaj   +1 more source

Monoclonal gammopathy and myeloproliferative neoplasm molecular diagnostics [PDF]

Hematology, Transfusion and Cell Therapy
Stephen E. Langabeer
doaj   +2 more sources

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort

Haematologica, 2019
Myeloid and lymphoid malignancies are postulated to have distinct pathogenetic mechanisms. The recent observation that patients with a myeloproliferative neoplasm have an increased risk of developing lymphoproliferative malignancy has challenged this ...
Johanne M. Holst, Trine L. Plesner, Martin B. Pedersen, Henrik Frederiksen, Michael B. Møller, Michael R. Clausen, Marcus C. Hansen, Stephen Jacques Hamilton-Dutoit, Peter Nørgaard, Preben Johansen, Tobias Ramm Eberlein, Bo K. Mortensen, Gustav Mathiasen, Andreas Øvlisen, Rui Wang, Chao Wang, Weiwei Zhang, Hans Beier Ommen, Jesper Stentoft, Maja Ludvigsen, Wayne Tam, Wing C. Chan, Giorgio Inghirami, Francesco d'Amore   +23 more
doaj   +1 more source

Myelodysplastic/Myeloproliferative Neoplasms

Seminars in Diagnostic Pathology, 2011
The myelodysplastic/myeloproliferative neoplasms (MDS/MPN) include clonal myeloid neoplasms that overlap the MDS and MPN categories and at the time of initial diagnosis exhibit some clinical, laboratory, or morphologic features supporting the diagnosis of myelodysplastic syndrome (MDS) and at the same time show proliferative features in keeping with ...
Elizabeth Hyjek, James W. Vardiman
openaire   +7 more sources

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow

Haematologica, 2012
We investigated 15,542 patients with suspected BCR-ABL1- negative myeloproliferative or myelodysplastic/myeloproliferative neoplasm (including 359 chronic myelomonocytic leukemia) by a molecular marker set.
Susanne Schnittger, Ulrike Bacher, Christiane Eder, Frank Dicker, Tamara Alpermann, Vera Grossmann, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach   +9 more
doaj   +1 more source

JAK2 rs10974944 is associated with both V617F‐positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker

Molecular Genetics & Genomic Medicine, 2022
The JAK2 gene encodes for a non‐receptor tyrosine kinase that plays a key role in the JAK/STAT signaling transfer pathway. Genetic polymorphisms of this gene have been indicated to be associated with myeloproliferative neoplasm‐associated thrombosis in ...
Nguyen Thy Ngoc, Bui Bich Hau, Nguyen Ba Vuong, Nguyen Thi Xuan   +3 more
doaj   +1 more source